Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

25 Jan 2010

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).

23 Jan 2010

Abaxis' new CRP assay receives FDA marketing clearance

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Research shows brain abnormalities develop years before Parkinson's symptoms appear

Scientists who have identified brain networks damaged in Parkinson's disease have new evidence that these systems become abnormal a few years before symptoms appear. And what's more, parts of the network appear to respond in a last ditch attempt to rescue the brain.

21 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

20 Jan 2010

New report providing insight for companies developing therapies to treat hematologic malignancies published

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.

18 Jan 2010

EMA PDCO grants specific waivers for Gamida Cell-Teva JV's StemEx study in paediatric patients

The Gamida Cell-Teva Joint Venture (JV) announced today that the Paediatric Committee (PDCO) of the EMA has granted product specific waivers for StemEx for all subsets of the paediatric population (birth to 17 years of age) in all conditions. The PDCO emphasized that the granting of the waivers should not prevent the JV from considering developing StemEx for children with conditions where there is a need. StemEx is being developed by a joint venture equally owned and operated by Gamida Cell and Teva Pharmaceuticals ( TEVA).

18 Jan 2010

Celgene acquires Gloucester Pharmaceuticals

Celgene Corporation today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

18 Jan 2010

New research shows cutting tobacco smoking reduces cancer deaths in Europe

New research on deaths from cancer in Europe concludes that the key priority for continuing to reduce mortality is cutting tobacco smoking. The study shows that, while deaths for men from lung cancer in the EU have declined overall, by 17 % from 1995 to 2004, they rose by 27% for women over the same period.

17 Jan 2010

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan.

13 Jan 2010

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.

13 Jan 2010

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

moksha8 and BioCryst today announced that moksha8 has been granted approval from COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) in Mexico for the importation and use of peramivir in patients with influenza associated with the 2009 H1N1 influenza A strain.

13 Jan 2010

4SC commences treatment in its resminostat Phase II trial for HL

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.

12 Jan 2010

BioCryst Pharmaceuticals signs agreements with two additional partners

BioCryst Pharmaceuticals, Inc. today announced that it has signed agreements with two additional partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities for territories outside of the U.S. BioCryst's new partners are Merck Serono for Europe, Russia, Canada and Singapore and Hikma Pharmaceuticals PLC for the Middle East and North Africa (MENA) region, excluding Israel.

12 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.

9 Jan 2010

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.

8 Jan 2010

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

The Canadian Cancer Society British Columbia and Yukon today called on the B.C. government to enact legislation to ban the cosmetic use of pesticides that would set a new national standard. The Society is also asking British Columbians to participate in the on-line public consultation.

8 Jan 2010

Lymphoma News and Research

Further Reading

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec's statement on FDA approval of AMPYRA

Abaxis' new CRP assay receives FDA marketing clearance

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Research shows brain abnormalities develop years before Parkinson's symptoms appear

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Fc engineering enhances antibody half-life

New report providing insight for companies developing therapies to treat hematologic malignancies published

EMA PDCO grants specific waivers for Gamida Cell-Teva JV's StemEx study in paediatric patients

Celgene acquires Gloucester Pharmaceuticals

New research shows cutting tobacco smoking reduces cancer deaths in Europe

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

4SC commences treatment in its resminostat Phase II trial for HL

BioCryst Pharmaceuticals signs agreements with two additional partners

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Green Cross seeks regulatory approval for peramivir in S.Korea

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News